Associate Director, Translational Medicine Lead. - Boston

AstraZeneca•Cambridge, MA
•$142,378 - $213,566

About The Position

AstraZeneca is seeking an Associate Director, Translational Medicine Lead for its Hematology R&D organization in Boston. The role leads hypothesis-driven biomarker strategies and translational science across B-cell malignancy programs, including B-cell acute lymphoblastic leukemia (B-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and non-Hodgkin lymphoma (NHL), including combination therapy studies. It translates disease biology and therapeutic mechanisms into plans for patient stratification and selection, target engagement, pharmacodynamic assessment, response depth and durability, and investigation of resistance mechanisms. The position supports large molecules, including T-cell-engaging bispecifics, antibody-drug conjugates, and monoclonal antibodies, as well as small molecules and cell-based therapies. The Associate Director is accountable for translational strategy for assigned programs and clinical trials, representing Translational Medicine in cross-functional program teams from preclinical development through Phase 1/2 and, when needed, Phase 3. The role collaborates with research, clinical development, clinical operations, clinical pharmacology, precision diagnostics, and other functions to deliver biomarker strategies, fit-for-purpose assays, translational data packages, and patient-selection approaches. It also contributes to portfolio decisions, regulatory materials, scientific communications, and external scientific engagement.

Requirements

  • PhD in a relevant biological science, such as hematology-oncology, immunology, oncology, molecular biology, or a related field; postdoctoral and/or industry experience is required.
  • Established knowledge of B-cell malignancy biology across B-ALL, B-CLL, and NHL, including disease pathogenesis, standard-of-care landscape, and therapeutic resistance mechanisms.
  • In-depth understanding of immunology and the tumor microenvironment in B-cell cancers and ability to apply this knowledge to translational strategy and biomarker design.
  • Demonstrated experience with T-cell-engaging bispecifics, such as CD3-targeting bispecifics or BiTEs, in an oncology or hematology development context; required.
  • Demonstrated experience with antibody-drug conjugates in a hematology or oncology development context; required.
  • 3–5 years of experience contributing to early-phase oncology clinical trials, including biomarker plan development, protocol input, and sample analysis.
  • Expertise in relevant biomarker technologies, such as flow cytometry, immunohistochemistry, molecular profiling, NGS, ctDNA, MRD assessment, cytokine or immune profiling, and other omics-based approaches.
  • Emerging understanding of end-to-end clinical development, from dose escalation through registration, and the strategic role of biomarkers at each stage.
  • Ability to work independently and deliver translational programs with regular managerial support, applying sound scientific judgment and prioritization without close oversight.
  • Proven ability to provide scientific leadership and work effectively in cross-functional program teams in a matrixed pharmaceutical or biotechnology environment.
  • Ability to present and integrate scientific data across experiments into a cohesive program narrative and articulate implications for Go/No-Go decisions, including risks and caveats.
  • Excellent communication and presentation skills for internal stakeholders and emerging external scientific audiences; comfort representing Translational Medicine in cross-functional governance settings.
  • Emerging awareness of AstraZeneca functions such as Regulatory, Medical, and Commercial and how Translational Medicine outputs inform them.

Nice To Haves

  • Experience with small-molecule hematology therapeutics in B-cell malignancies, such as BTK or BCL-2 inhibitors, and familiarity with combination treatment strategies.
  • Exposure to cell therapy programs, such as CAR-T or other engineered cell therapies, in B-cell leukemia or lymphoma.
  • Familiarity with MRD methodologies, including flow cytometry and/or NGS-based approaches, in leukemia or lymphoma clinical development.
  • Experience integrating multi-omic biomarker data, such as flow cytometry, ctDNA, cytokine panels, and transcriptomics, to support clinical decisions across combination regimens.
  • Familiarity with regulatory expectations for biomarker analytical validation and companion diagnostic development.
  • Early experience mentoring junior scientists and interest in contributing to team capability development.
  • Exposure to Phase 3 trial biomarker strategies.

Responsibilities

  • Develop and own translational science strategies for assigned B-cell malignancy programs from preclinical stages through Phase 1/2 and Phase 3 clinical studies.
  • Generate and integrate disease-linkage data to support indication selection, patient stratification, and definition of target populations in monotherapy and combination studies.
  • Measure and interpret target engagement, pharmacodynamic biomarkers, and mechanism-of-action data to inform dose selection and clinical decisions across multiple programs or trials.
  • Define and investigate resistance mechanisms to B-cell-targeted therapies across modalities using longitudinal and relapse clinical samples.
  • Analyze B-cell tumor biology, cancer pathway interactions, and tumor microenvironment features in patient samples to guide drug-combination strategies and trial design.
  • Lead development and deployment of fit-for-purpose translational assays, including flow cytometry, IHC/IF, molecular assays, and MRD-adjacent panels, internally and through external CRO or laboratory partners.
  • Collaborate with Precision Diagnostics on sample collection, traceability, and documentation, and support companion diagnostic pathway discussions where appropriate.
  • Contribute translational and biomarker content to regulatory interactions and filings, including health-authority briefing materials where appropriate.
  • Represent Translational Medicine on program-level cross-functional teams and partner with Clinical Development, Oncology Research, Clinical Operations, and Product Development to align translational work with asset strategy, disease biology, and development milestones.
  • Embed biomarker strategies and translational endpoints in clinical protocols, sample collection manuals, statistical analysis plans, and data-delivery schedules for hematology studies from Phase 1 through Phase 3.
  • Contribute to translational strategy across the B-cell hematology portfolio, using program insights to inform indication expansion and combination hypotheses.
  • Partner with preclinical discovery teams so translational insights inform early compound selection and target validation.
  • Contribute to and ensure the quality of clinical study reports, data reviews, scientific presentations, and recommendations for program governance and Go/No-Go decisions.
  • Integrate translational findings across experiments and studies into a coherent scientific narrative for program and portfolio decisions.
  • Communicate biomarker findings to internal stakeholders, including governance forums and leadership teams, explaining strategic implications, risks, and data caveats.
  • Contribute to scientific publications and conference presentations and represent AstraZeneca at external scientific forums in B-cell malignancy translational research.

Benefits

  • Eligibility for short-term incentive bonuses.
  • Equity-based awards for salaried roles.
  • Qualified retirement programs.
  • Paid time off, including vacation, holidays, and leaves.
  • Health coverage.
  • Dental coverage.
  • Vision coverage.

Stand Out From the Crowd

Upload your resume and get instant feedback on how well it matches this job.

Upload and Match Resume

What This Job Offers

Job Type

Full-time

Career Level

Director

Education Level

Ph.D. or professional degree

© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service